Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Frank Brisebois who wrote (8239)	10/25/1999 9:46:00 AM
From: manny t	Read Replies (1) \| Respond to of 9523

Painne Weber downgrades to Neutral from Buy. Manny T.

To: Frank Brisebois who wrote (8239)	10/25/1999 11:43:00 AM
From: Joe S Pack	Respond to of 9523

Pain Webber caught napping. Their customer wants to load. Down graded with 12 months target of 42 (another joke). -Nat

To: Frank Brisebois who wrote (8239)	10/25/1999 6:21:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

Bloomberg article on the downgrade: cnetinvestor.com The fact that PFE closes at $40, its recent breakout point and near the high of the day, is encouraging. All the major pharmas have something against them: with MRK it's the drugs that is going off patent in the next 2 years, with WLA it's the heavy dependence on Lipitor for most of its revenues. If the pharmaceuticals as a group is turning up again, it is quite unlikely that PFE alone would buck the trend and stay in the mid 30's.